Concurrently, the Gal residues in RGPPN could combine specifically with ASGPR in liver (Ishibashi et al., 1994; Rigopoulou et al., 2012) such that RGPPN could have an active targeting effect to the liver and play a more effective therapeutic role for liver cancer. This evidence concerns the gene GAL and liver cancer.